D.A. Vorobiof

2.7k total citations
6 papers, 11 citations indexed

About

D.A. Vorobiof is a scholar working on Oncology, Economics and Econometrics and Reproductive Medicine. According to data from OpenAlex, D.A. Vorobiof has authored 6 papers receiving a total of 11 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Oncology, 2 papers in Economics and Econometrics and 2 papers in Reproductive Medicine. Recurrent topics in D.A. Vorobiof's work include Economic and Financial Impacts of Cancer (2 papers), Ovarian cancer diagnosis and treatment (2 papers) and Cancer therapeutics and mechanisms (1 paper). D.A. Vorobiof is often cited by papers focused on Economic and Financial Impacts of Cancer (2 papers), Ovarian cancer diagnosis and treatment (2 papers) and Cancer therapeutics and mechanisms (1 paper). D.A. Vorobiof collaborates with scholars based in United Kingdom, Israel and South Africa. D.A. Vorobiof's co-authors include Ulrich R. Kleeberg, Mitch Dowsett, Bernardo L. Rapoport, David Dodwell, J.F.R. Robertson, C. Slabber, Andrey Litvin, Johann Raats, Martin Chasen and Einav Sapir and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and International Journal of Gynecological Cancer.

In The Last Decade

D.A. Vorobiof

6 papers receiving 10 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D.A. Vorobiof United Kingdom	3	7	5	4	3	2	6	11
Filipa Cardoso Portugal	3	7 1.0×	4 0.8×	4 1.0×		2 1.0×	7	14
A. Fernandez Ortega Spain	2	8 1.1×	3 0.6×	3 0.8×		4 2.0×	4	10
Evgeny Imyanitov Russia	2	5 0.7×	2 0.4×	5 1.3×	2 0.7×		2	12
Sebastián Navarrete Chile	1	4 0.6×	4 0.8×	4 1.0×			3	4
William Varnado United States	1	7 1.0×	8 1.6×	2 0.5×		3 1.5×	2	21
Khalis Mitchell United States	2	9 1.3×	5 1.0×	4 1.0×		7 3.5×	2	15
Pardeep Arora United Kingdom	2	5 0.7×	2 0.4×	3 0.8×			4	9
Heba Baraka Palestinian Territory	2	8 1.1×	4 0.8×	2 0.5×			3	11
Mary Kay Hardwick United States	2	3 0.4×	3 0.6×	3 0.8×		2 1.0×	3	7
Michael Eubank United States	2	5 0.7×	9 1.8×	2 0.5×		3 1.5×	2	16

Countries citing papers authored by D.A. Vorobiof

Since Specialization

Citations

This map shows the geographic impact of D.A. Vorobiof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.A. Vorobiof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.A. Vorobiof more than expected).

Fields of papers citing papers by D.A. Vorobiof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.A. Vorobiof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.A. Vorobiof. The network helps show where D.A. Vorobiof may publish in the future.

Co-authorship network of co-authors of D.A. Vorobiof

This figure shows the co-authorship network connecting the top 25 collaborators of D.A. Vorobiof. A scholar is included among the top collaborators of D.A. Vorobiof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.A. Vorobiof. D.A. Vorobiof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Sapir, Einav, et al.. (2021). 1594P SARS-CoV-2 vaccines in cancer patients (pts), real-world data (RWD) from 1069 Belong.life users. Annals of Oncology. 32. S1144–S1144. 1 indexed citations

2.

Vorobiof, D.A., et al.. (2020). 1612P Real-world evidence data (RWED) of financial toxicity (FT) in cancer patients (pts) receiving immunotherapy drugs (IOT). Annals of Oncology. 31. S969–S969. 1 indexed citations

3.

Rapoport, Bernardo L., et al.. (2019). Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer. Annals of Oncology. 30. ii61–ii61. 2 indexed citations

4.

Vorobiof, D.A., et al.. (2003). Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy. International Journal of Gynecological Cancer. 13(3). 287–291. 2 indexed citations

5.

Vorobiof, D.A., Bernardo L. Rapoport, André Uys, et al.. (2003). 179 A phase II second line study of liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer with a disease free interval equal or greater than 6 months. European Journal of Cancer Supplements. 1(5). S57–S57. 1 indexed citations

6.

Dowsett, Mitch, et al.. (1996). PP-8-5 A randomised study assessing oestrogen suppression with arimidex™ (Anastrozole) and formestane in postmenopausal advanced breast cancer (ABC) patients. European Journal of Cancer. 32. 49–50. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact